| Published Application/Species/Sample/Dilution | Reference |
|---|
| Murakami S, Matsumoto R, Kanamori T. Constructive approach for synthesis of a functional IgG using a reconstituted cell-free protein synthesis system. Sci Rep. 2019;9:671 pubmed publisher |
| Albers A, Garofalo A, Drake P, Kudirka R, de Hart G, Barfield R, et al. Exploring the effects of linker composition on site-specifically modified antibody-drug conjugates. Eur J Med Chem. 2014;88:3-9 pubmed publisher |
| Wang Y, Zhang G, Rong P, Guo P, Huang S, Hang Y, et al. Intrinsic/proximal cell surface marker logic-gated extracellular targeted protein degradation in specific cell population. Mol Ther. 2025;33:3644-3661 pubmed publisher |
| Ahn D, Park S, Lee Y, Jeong M, Gone G, Cho Y, et al. Enhanced Targeted Drug Delivery System to Control Avidity and Drug Encapsulation Using E2 Nanocages and SpyTag/SpyCatcher. ACS Biomater Sci Eng. 2025;11:2768-2782 pubmed publisher |
| Tsao L, Wang J, Ma X, Sodhi S, Ragusa J, Liu B, et al. Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd). Nat Commun. 2025;16:3167 pubmed publisher |
| Westerberg C, Mestre Borras A, St xe5 hl S, L xf6 fblom J. Affibody-based HER2 prodrug shows conditional cytotoxic effect on HER2-positive cancer cells. Biochem Biophys Res Commun. 2025;758:151660 pubmed publisher |
| Zhang M, Yang Q, Lou J, Hu Y, Shi Y. A new strategy to HER2-specific antibody discovery through artificial intelligence-powered phage display screening based on the Trastuzumab framework. Biochim Biophys Acta Mol Basis Dis. 2025;1871:167772 pubmed publisher |
| Reiss K, Angelos M, Dees E, Yuan Y, Ueno N, Pohlmann P, et al. CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial. Nat Med. 2025;31:1171-1182 pubmed publisher |
| Pierini S, Gabbasov R, Oliveira Nunes M, Qureshi R, Worth A, Huang S, et al. Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models. Nat Commun. 2025;16:706 pubmed publisher |
| Fournier L, Pekar L, Leuthner B, Kolmar H, Toleikis L, Becker S. Discovery of potent allosteric antibodies inhibiting EGFR. MAbs. 2024;16:2406548 pubmed publisher |
| McCue A, Demarest S, Froning K, Hickey M, Antonysamy S, Kuhlman B. Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy. MAbs. 2024;16:2373325 pubmed publisher |
| Long A, Xu H, Santich B, Guo H, Hoseini S, de Stanchina E, et al. Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma. J Hematol Oncol. 2024;17:20 pubmed publisher |
| Koga H, Kuroi H, Hirano R, Hirayama H, Nabuchi Y, Kuramochi T. Rapid Generation of Murine Bispecific Antibodies Using FAST-IgTM for Preclinical Screening of HER2/CD3 T-Cell Engagers. Antibodies (Basel). 2024;13: pubmed publisher |
| Guo M, Zhao K, Guo L, Zhou R, He Q, Lu K, et al. Copper assisted sequence-specific chemical protein conjugation at a single backbone amide. Nat Commun. 2023;14:8063 pubmed publisher |
| Huo Y, Zhang H, Sa L, Zheng W, He Y, Lyu H, et al. M1 polarization enhances the antitumor activity of chimeric antigen receptor macrophages in solid tumors. J Transl Med. 2023;21:225 pubmed publisher |
| Chabrol E, Fagnen C, Landron S, Marcheteau E, Stojko J, Guenin S, et al. Biochemistry, structure, and cellular internalization of a four nanobody-bearing Fc dimer. Protein Sci. 2021;30:1946-1957 pubmed publisher |
| Park H, Kim Y, Yoo T. One-pot colorimetric detection of molecules based on proximity proteolysis reaction. Biosens Bioelectron. 2021;188:113349 pubmed publisher |
| Conilh L, Fournet G, Fourmaux E, Murcia A, Matera E, Joseph B, et al. Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform. Pharmaceuticals (Basel). 2021;14: pubmed publisher |
| Shi R, Xiao G, Dillon T, McAuley A, Ricci M, Bondarenko P. Identification of critical chemical modifications by size exclusion chromatography of stressed antibody-target complexes with competitive binding. MAbs. 2021;13:1887612 pubmed publisher |
| Leeman M, Albers W, Bombera R, Kuncová Kallio J, Tuppurainen J, Nilsson L. Asymmetric flow field-flow fractionation coupled to surface plasmon resonance detection for analysis of therapeutic proteins in blood serum. Anal Bioanal Chem. 2021;413:117-127 pubmed publisher |
| Pekar L, Busch M, Valldorf B, Hinz S, Toleikis L, Krah S, et al. Biophysical and biochemical characterization of a VHH-based IgG-like bi- and trispecific antibody platform. MAbs. 2020;12:1812210 pubmed publisher |
| Bansal R, Elgundi Z, Goodchild S, Care A, Lord M, Rodger A, et al. The Effect of Oligomerization on A Solid-Binding Peptide Binding to Silica-Based Materials. Nanomaterials (Basel). 2020;10: pubmed publisher |
| Klichinsky M, Ruella M, Shestova O, Lu X, Best A, Zeeman M, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020;38:947-953 pubmed publisher |
| Kim J, Suh J, Yang J. Labeling-free detection of ECD-HER2 protein using aptamer-based nano-plasmonic sensor. Nanotechnology. 2020;31:175501 pubmed publisher |
| Su C, Lua W, Ling W, Gan S. Allosteric Effects between the Antibody Constant and Variable Regions: A Study of IgA Fc Mutations on Antigen Binding. Antibodies (Basel). 2018;7: pubmed publisher |
| Hartmann L, Botzanowski T, Galibert M, Jullian M, Chabrol E, Zeder Lutz G, et al. VHH characterization. Comparison of recombinant with chemically synthesized anti-HER2 VHH. Protein Sci. 2019;28:1865-1879 pubmed publisher |
| Ramos J, Vega J, Cruz V, Sánchez Sánchez E, Cortes J, Martinez Salazar J. Hydrodynamic and Electrophoretic Properties of Trastuzumab/HER2 Extracellular Domain Complexes as Revealed by Experimental Techniques and Computational Simulations. Int J Mol Sci. 2019;20: pubmed publisher |
| Hu F, Lundqvist M, Uhlen M, Rockberg J. SAMURAI (Solid-phase Assisted Mutagenesis by Uracil Restriction for Accurate Integration) for antibody affinity maturation and paratope mapping. Nucleic Acids Res. 2019;47:e34 pubmed publisher |
| Lombana T, Matsumoto M, Berkley A, Toy E, Cook R, Gan Y, et al. High-resolution glycosylation site-engineering method identifies MICA epitope critical for shedding inhibition activity of anti-MICA antibodies. MAbs. 2019;11:75-93 pubmed publisher |
| Huang S, Li F, Liu H, Ye P, Fan X, Yuan X, et al. Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody. MAbs. 2018;10:864-875 pubmed publisher |
| Hollevoet K, De Smidt E, Geukens N, Declerck P. Prolonged in vivo expression and anti-tumor response of DNA-based anti-HER2 antibodies. Oncotarget. 2018;9:13623-13636 pubmed publisher |
| Yu F, Alesand V, Nygren P. Site-Specific Photoconjugation of Beta-Lactamase Fragments to Monoclonal Antibodies Enables Sensitive Analyte Detection via Split-Enzyme Complementation. Biotechnol J. 2018;13:e1700688 pubmed publisher |
| Lua W, Ling W, Yeo J, Poh J, Lane D, Gan S. The effects of Antibody Engineering CH and CL in Trastuzumab and Pertuzumab recombinant models: Impact on antibody production and antigen-binding. Sci Rep. 2018;8:718 pubmed publisher |
| Lua W, Gan S, Lane D, Verma C. A search for synergy in the binding kinetics of Trastuzumab and Pertuzumab whole and F(ab) to Her2. NPJ Breast Cancer. 2015;1:15012 pubmed publisher |
| Vega J, Ramos J, Cruz V, Vicente Alique E, Sánchez Sánchez E, Sánchez Fernández A, et al. Molecular and hydrodynamic properties of human epidermal growth factor receptor HER2 extracellular domain and its homodimer: Experiments and multi-scale simulations. Biochim Biophys Acta Gen Subj. 2017;1861:2406-2416 pubmed publisher |
| Su C, Ling W, Lua W, Poh J, Gan S. The role of Antibody Vκ Framework 3 region towards Antigen binding: Effects on recombinant production and Protein L binding. Sci Rep. 2017;7:3766 pubmed publisher |
| Aubé A, Campbell S, Schmitzer A, Claing A, Masson J. Ultra-low fouling alkylimidazolium modified surfaces for the detection of HER2 in breast cancer cell lysates [corrected]. Analyst. 2017;142:2343-2353 pubmed publisher |
| Eletxigerra U, Martinez Perdiguero J, Barderas R, Pingarrón J, Campuzano S, Merino S. Surface plasmon resonance immunosensor for ErbB2 breast cancer biomarker determination in human serum and raw cancer cell lysates. Anal Chim Acta. 2016;905:156-62 pubmed publisher |
| Nilvebrant J, Astrand M, Georgieva Kotseva M, Björnmalm M, Löfblom J, Hober S. Engineering of bispecific affinity proteins with high affinity for ERBB2 and adaptable binding to albumin. PLoS ONE. 2014;9:e103094 pubmed publisher |
| Gilabert Oriol R, Thakur M, von Mallinckrodt B, Hug T, Wiesner B, Eichhorst J, et al. Modified trastuzumab and cetuximab mediate efficient toxin delivery while retaining antibody-dependent cell-mediated cytotoxicity in target cells. Mol Pharm. 2013;10:4347-57 pubmed publisher |
| Kim K, Song J, Kee J, Liu Q, Lo G, Park M. Label-free biosensor based on an electrical tracing-assisted silicon microring resonator with a low-cost broadband source. Biosens Bioelectron. 2013;46:15-21 pubmed publisher |
| Zdobnova T, Stremovskiy O, Lebedenko E, Deyev S. Self-assembling complexes of quantum dots and scFv antibodies for cancer cell targeting and imaging. PLoS ONE. 2012;7:e48248 pubmed publisher |
| Münch R, Janicki H, Völker I, Rasbach A, Hallek M, Buning H, et al. Displaying high-affinity ligands on adeno-associated viral vectors enables tumor cell-specific and safe gene transfer. Mol Ther. 2013;21:109-18 pubmed publisher |
| Liu Z, Duan J, Song Y, Ma J, Wang F, Lu X, et al. Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro. J Transl Med. 2012;10:148 pubmed publisher |
| Markiv A, Beatson R, Burchell J, Durvasula R, Kang A. Expression of recombinant multi-coloured fluorescent antibodies in gor -/trxB- E. coli cytoplasm. BMC Biotechnol. 2011;11:117 pubmed publisher |
